key: cord-0762026-6dvg2zhg
authors: Xiao, Wenwei; Xu, Jie; Liang, Xuan; Shi, Li; Zhang, Peihua; Wang, Yadong; Yang, Haiyan
title: Relationship between chronic kidney disease and adverse outcomes of coronavirus disease 2019: a meta-analysis based on adjusted risk estimates
date: 2021-01-02
journal: Int Urol Nephrol
DOI: 10.1007/s11255-020-02748-9
sha: 708e9db44f8d66a59f509d37653975cb2270ca24
doc_id: 762026
cord_uid: 6dvg2zhg

nan

assessed by sensitivity analysis. Publication bias was evaluated by Begg's test and Egger's test.

A total of 179 articles were identified. Finally, 13 articles with 12,999 patients were included in the study. The main characteristics of the included studies are shown in Table 1 .

Our results indicated that COVID-19 patients with a history of CKD had an increased risk for adverse outcomes (pooled effect = 1.64, 95% CI 1.28-2.09) (Fig. 1a) . We also observed that CKD was significantly associated with an increased risk for COVID-19 death while adverse outcomes were only restricted to death (pooled effect = 1.67, 95% CI 1.28-2.17) (Fig. 1b) . There was no publication bias (Begg's test, P = 0.855 (Fig. 1c) and Egger's test, P = 0.655). Sensitivity analysis exhibited that our results were stable (Fig. 1d) .

Previous meta-analyses have reported the association of CKD with poor outcomes including mortality among COVID-19 patients, but their findings were based on unadjusted effect estimates [5] [6] [7] [8] [9] [10] . Our present study based on adjusted effect estimates indicated that pre-existing CKD was independently associated with an increased risk for adverse outcomes, especially for mortality. Thus, co-existing CKD patients should be taken care not to get COVID-19 infection. Of course, there are some limitations to this study. First, the patients in each article might be in different stages of the disease, which may have a certain impact on the overall effects. Second, supportive treatment and medications are not clear in the included studies, thus, the data could not be analyzed currently. Third, the included studies were mainly from China, USA and Italy. As a result, it should be cautious to extrapolate the inclusion to other regions. Fourth, the findings were based on the adjusted effect estimates, but the adjusted factors were not completely consistent. This issue should be addressed in the future studies. Taken together, our current study is needed to be verified by further welldesigned studies with a large sample size. 

Risk factors for disease progression in patients with mild to moderate coronavirus disease 2019-a multi-centre observational study

Fasting blood glucose at admission is an independent predictor for 28-day mortality in patients with COVID-19 without previous diagnosis of diabetes: a multi-centre retrospective study

Epidemiological, comorbidity factors with severity and prognosis of COVID-19: a systematic review and meta-analysis

Obesity is a risk factor for developing critical condition in COVID-19 patients: a systematic review and meta-analysis

Coronavirus disease (COVID-19): a systematic review and meta-analysis to evaluate the impact of various comorbidities on serious events

Prevalence of co-morbidities and their association with mortality in patients with COVID-19: a systematic review and meta-analysis

Association of cardiovascular disease and 10 other pre-existing comorbidities with COVID-19 mortality: a systematic review and meta-analysis

Comorbid chronic diseases and acute organ injuries are strongly correlated with disease severity and mortality among COVID-19 patients: a systemic review and meta-analysis

The association between chronic kidney disease and new onset renal replacement therapy on the outcome of COVID-19 patients: a meta-analysis

Prognosis of COVID-19 in patients with liver and kidney diseases: an early systematic review and meta-analysis

We would like to thank Ying Wang, Hongjie Hou,